523 related articles for article (PubMed ID: 26473447)
41. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract][Full Text] [Related]
42. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
[TBL] [Abstract][Full Text] [Related]
43. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils.
Andina N; Didichenko S; Schmidt-Mende J; Dahinden CA; Simon HU
J Allergy Clin Immunol; 2009 Mar; 123(3):603-11. PubMed ID: 19152965
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
45. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
46. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
47. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
48. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
[TBL] [Abstract][Full Text] [Related]
49. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
50. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
51. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
52. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
[TBL] [Abstract][Full Text] [Related]
53. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ
Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875
[TBL] [Abstract][Full Text] [Related]
54. PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes.
Ha YJ; Choi YS; Han DW; Kang EH; Yoo IS; Kim JH; Kang SW; Lee EY; Song YW; Lee YJ
Rheumatology (Oxford); 2019 Jan; 58(1):154-164. PubMed ID: 30204915
[TBL] [Abstract][Full Text] [Related]
55. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
Cheng F; Wang L; Shen Y; Xia J; Chen H; Jiang Y; Lu M
Biochem Biophys Res Commun; 2016 Feb; 470(2):324-330. PubMed ID: 26792718
[TBL] [Abstract][Full Text] [Related]
56. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
57. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia.
Hadley G; Beard DJ; Alexopoulou Z; Sutherland BA; Buchan AM
Neurosci Lett; 2019 Jul; 706():223-230. PubMed ID: 31100427
[TBL] [Abstract][Full Text] [Related]
58. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
[TBL] [Abstract][Full Text] [Related]
59. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.
Vachhani P; Bose P; Rahmani M; Grant S
Physiol Genomics; 2014 Jul; 46(13):448-56. PubMed ID: 24824212
[TBL] [Abstract][Full Text] [Related]
60. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
